The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.

@article{Gurbel2014TheEO,
  title={The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.},
  author={Paul A Gurbel and Thomas O. Bergmeijer and Udaya S. Tantry and Jurri{\"e}n Maria ten Berg and Dominick Joseph Angiolillo and Stefan James and Tomas L Lindahl and Peter Svensson and Joseph A. Jakubowski and Patricia B Brown and S. Duvvuru and Scott S. Sundseth and Joseph R. Walker and David G. Small and Brian A. Moser and Kenneth J. Winters and David Erlinge},
  journal={Thrombosis and haemostasis},
  year={2014},
  volume={112 3},
  pages={589-97}
}
CYP2C19 genotype has been shown to impact response to clopidogrel 75-mg but not prasugrel 10-mg. Here, we assessed effects of CYP2C19 metaboliser status on pharmacokinetics (PK) and pharmacodynamic (PD) responses to prasugrel 5-mg and 10-mg and clopidogrel 75-mg using data from two PK/PD studies in stable coronary artery disease (CAD) patients (GENERATIONS… CONTINUE READING